NCT06860594

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2025-07-30Est. Completion: 2027-06-30

Enrollment target: 30 participants

Locations

City of Hope Comprehensive Cancer Center, Duarte, California, United States
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Yale University, New Haven, Connecticut, United States
Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States
MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
UM Sylvester Comprehensive Cancer Center at Coral Springs, Coral Springs, Florida, United States
UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
UM Sylvester Comprehensive Cancer Center at Doral, Doral, Florida, United States
UM Sylvester Comprehensive Cancer Center at Hollywood, Hollywood, Florida, United States

Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade III

The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of…

Chicago, United StatesEst. completion Sep 2028

IDH-mutant Grade 2 or 3 Astrocytoma

The main goal of VIGOR is to demonstrate that vorasidenib maintenance therapy improves locally assessed progression-free…

Innsbruck, AustriaEst. completion Apr 13, 2035

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.